A detailed history of Soleus Capital Management, L.P. transactions in Evolus, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 1,037,680 shares of EOLS stock, worth $11.3 Million. This represents 1.43% of its overall portfolio holdings.

Number of Shares
1,037,680
Previous 1,152,000 9.92%
Holding current value
$11.3 Million
Previous $12.5 Million 34.49%
% of portfolio
1.43%
Previous 1.27%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.66 - $17.48 $1.22 Million - $2 Million
-114,320 Reduced 9.92%
1,037,680 $16.8 Million
Q2 2024

Aug 14, 2024

BUY
$10.45 - $13.76 $10.4 Million - $13.6 Million
992,000 Added 620.0%
1,152,000 $12.5 Million
Q1 2024

May 15, 2024

BUY
$9.99 - $14.91 $1.6 Million - $2.39 Million
160,000 New
160,000 $2.24 Million
Q3 2023

Nov 14, 2023

BUY
$7.15 - $10.2 $7.59 Million - $10.8 Million
1,061,000 Added 104.33%
2,078,000 $19 Million
Q2 2023

Aug 14, 2023

BUY
$7.23 - $10.52 $7.35 Million - $10.7 Million
1,017,000 New
1,017,000 $7.39 Million
Q2 2022

Aug 15, 2022

SELL
$10.22 - $13.94 $5.7 Million - $7.77 Million
-557,713 Reduced 40.76%
810,676 $9.4 Million
Q1 2022

May 16, 2022

BUY
$5.22 - $11.78 $571,590 - $1.29 Million
109,500 Added 8.7%
1,368,389 $15.4 Million
Q4 2021

Feb 14, 2022

BUY
$5.37 - $8.38 $3.31 Million - $5.16 Million
615,955 Added 95.8%
1,258,889 $8.2 Million
Q3 2021

Nov 15, 2021

BUY
$7.36 - $13.67 $463,194 - $860,307
62,934 Added 10.85%
642,934 $4.9 Million
Q2 2021

Aug 16, 2021

BUY
$8.42 - $13.96 $4.88 Million - $8.1 Million
580,000 New
580,000 $7.34 Million

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $609M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.